TY - JOUR
T1 - Characterization of a synthetic anionic vector for oligonucleotide delivery using in Vivo whole body dynamic imaging
AU - Tavitian, B.
AU - Marzabal, S.
AU - Boutet, V.
AU - Kühnast, B.
AU - Terrazzino, S.
AU - Moynier, M.
AU - Dollé, F.
AU - Deverre, J. R.
AU - Thierry, A. R.
N1 - Funding Information:
We thank Dr Marc Joliot (Cyceron, Caen) for the image normalization software and Antoinette Jobert (INSERM U 334) for help with the animal experiments. Supported in part by Biomed2 contract N° BMH4-CT96-1067, MESR ACC-SV12 contract N° 2654, and the Association Française contre les Myopathies.
PY - 2002
Y1 - 2002
N2 - Purpose. To compare the pharmacokinetics and bioavailability of an oligonucleotide delivered in a free form or using cationic or anionic synthetic carrier systems. Methods. Whole body dynamic quantitative imaging and metabolism of a HIV antisense oligonucleotide intravenously administered either free or incorporated into synthetic carriers were compared in baboons, using non invasive positron emission tomography and an enzyme-based competitive hybridization assay, respectively. Results. In its free form, the oligonucleotide showed high liver and kidney concentration, rapid plasmatic degradation and elimination from the body. Use of a cationic vector slightly protected the oligonucleotide against degradation and enhanced uptake by the reticulo-endothelial system. In contrast, the anionic vector dramatically enhanced the uptake in several organs, including the lungs, spleen and brain, with a prolonged accumulation of radioactivity in the brain. Using this vector, intact oligonucleotide was detected in plasma for up to two hours after injection, and the T1/2β and distribution volume increased by 4- and 7-fold, respectively. No evidence of toxicity was found after a single dose administration. Conclusions. The anionic vector improves significantly the bioavailability and the pharmacokinetics of the oligonucleotide, and is a promising delivery system for in vivo administration of therapeutic nucleic acids.
AB - Purpose. To compare the pharmacokinetics and bioavailability of an oligonucleotide delivered in a free form or using cationic or anionic synthetic carrier systems. Methods. Whole body dynamic quantitative imaging and metabolism of a HIV antisense oligonucleotide intravenously administered either free or incorporated into synthetic carriers were compared in baboons, using non invasive positron emission tomography and an enzyme-based competitive hybridization assay, respectively. Results. In its free form, the oligonucleotide showed high liver and kidney concentration, rapid plasmatic degradation and elimination from the body. Use of a cationic vector slightly protected the oligonucleotide against degradation and enhanced uptake by the reticulo-endothelial system. In contrast, the anionic vector dramatically enhanced the uptake in several organs, including the lungs, spleen and brain, with a prolonged accumulation of radioactivity in the brain. Using this vector, intact oligonucleotide was detected in plasma for up to two hours after injection, and the T1/2β and distribution volume increased by 4- and 7-fold, respectively. No evidence of toxicity was found after a single dose administration. Conclusions. The anionic vector improves significantly the bioavailability and the pharmacokinetics of the oligonucleotide, and is a promising delivery system for in vivo administration of therapeutic nucleic acids.
KW - Antisense oligonucleotide
KW - In vivo delivery
KW - Neutraplex
KW - Pharmacokinetics
KW - Positron emission tomography (PET)
UR - http://www.scopus.com/inward/record.url?scp=0036112087&partnerID=8YFLogxK
U2 - 10.1023/A:1015133205457
DO - 10.1023/A:1015133205457
M3 - Article
SN - 0724-8741
VL - 19
SP - 367
EP - 376
JO - Pharmaceutical Research
JF - Pharmaceutical Research
IS - 4
ER -